Challenges in Treating Cardiovascular Disease: Restricting Sodium and Managing Hyperkalemia

Area of Science:

• Cardiology
• Nephrology
• Pharmacology

Background:

• High sodium intake is linked to increased cardiorenal risk, hypertension, and reduced efficacy of key cardiovascular and kidney disease medications.
• Potassium plays a counter-regulatory role, but its management (hyperkalemia) can limit optimal treatment with renin-angiotensin-aldosterone system inhibitors.

Purpose of the Study:

• To review the impact of sodium intake on cardiorenal risk and treatment efficacy.
• To evaluate potassium binders, particularly novel agents that do not increase sodium load, for managing hyperkalemia in patients at high cardiorenal risk.

Main Methods:

• Literature search of PubMed using terms: potassium, sodium, hyperkalemia, potassium binders.
• Focus on recent publications (post-2000) relevant to cardiorenal risk and potassium management.

Main Results:

• High sodium intake exacerbates cardiorenal risk and hinders renin-angiotensin-aldosterone system inhibitor effectiveness.
• Potassium binders are crucial for managing hyperkalemia, a common limitation in treatment.
• Novel potassium binders using non-sodium exchange ions offer an advantage by not increasing sodium load.

Conclusions:

• Reducing sodium intake is essential for mitigating cardiorenal risk.
• Careful management of potassium levels is critical, especially when using renin-angiotensin-aldosterone system inhibitors.
• Potassium binders that avoid increasing sodium intake are preferable for patients at high cardiorenal risk to prevent adverse outcomes.